BIOQUANT
BIOQUANT > Research Groups > Genome Organisation & Function > People > Alexandra Poos

Alexandra Poos

Research Interest

Multiple myeloma (MM) is a heterogeneous disorder of clonal plasma cells that accumulate in the bone marrow. The vast majority of patients relapses at some point but the mechanisms leading to relapse or treatment resistance have not been sufficiently characterized. To study the inter- and intratumor heterogeneity of relapsed/refractory (RR)MM we generated single cell gene expression (scRNA-seq) and chromatin accessibility (scATAC-seq) data of RRMM patients before and after treatment. Using an integrative analysis we explore the clonal heterogeneity of the patients, identify marker genes that change their expression or chomatin state upon treatment and study the underlying regulatory mechanisms by constructing gene regulatory networks.

Scientific Background

  • since 03/2019 Postdoc at the University Hospital Heidelberg in the group of Prof. Marc Raab (Department of Internal Medicine V, Section Multiple Myeloma); in collaboration with the group of Prof. Karsten Rippe
  • 05/2019: PhD at the University of Heidelberg (Faculty of Biosciences); Thesis Title: “Mixed Integer Linear Programming based approaches to study telomere maintenance mechanisms”; supervisors: Prof. Karsten Rippe and Prof. Rainer König
  • 10/2014 – 02/2019: PhD student at the University Hospital Jena in the “Systemsbiology of sepsis” group headed by Prof. Rainer König
  • 11/2013 – 06/2014: Master thesis “Identifying regulators of the telomerase in Saccharomyces cerevisiae employing Mixed Integer Linear Programming approaches” in the Division of Theoretical Bioinformatics at the German Cancer Research Center (Network Modeling Group, Prof. Rainer König)
  • 10/2011 – 08/2014: University of Heidelberg - Master program of Molecular Biotechnology (major: Bioinformatics)
  • 10/2008 – 09/2011: University of Heidelberg - Bachelor program of Molecular Biotechnology

Publications

  • Poos AM, Kordaß T, Kolte A, Ast V, Oswald M, Rippe K, König R (2019). Modelling TERT regulation across 19 different cancer types based on the MIPRIP gene regulatory network approach. BMC Bioinformatics, in revision.
  • Mallm JP, Iskar M, Ishaque N, Klett LC, Kugler SJ, Muino JM, Teif VB, Poos AM, Großmann S, Erdel F, Tavernari D, Koser SD, Schumacher S, Brors B, König R, Remondini D, Vingron M, Stilgenbauer S, Lichter P, Zapatka M, Mertens D, Rippe K (2019). Linking aberrant chromatin features in chronic lymphocytic leukemia to deregulated transcription factor networks. Mol Syst Biol 15, e8339.
  • Höflmayer D, Soltow A, Hube-Magg C, Kluth M, Simon R, Burandt E, Tsourlakis MC, Minner S, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos AM, Oswald M, Rippe K, König R, Schroeder C (2019). High expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in ERG-negative prostate cancer. Molecular Oncology, accepted.
  • Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jabobsen F, Hinsch A, Poos AM, Oswald M, Rippe K, König R, Schroeder C (2019) Loss of CCAAT/Enhancer binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. The Prostate 79(3):302-311.
  • Deeg KI, Chung I, Poos AM, Braun DM, Korshunov A, Oswald M, Kepper N, Bender S, Castel D, Lichter P, Grill J, Pfister SM, König R, Jones DTW, Rippe K (2017). Dissecting the alternative lengthening of telomeres pathway in pediatric glioblastoma. bioRxiv 129106; doi: https://doi.org/10.1101/129106.
  • Poos AM, Maicher A, Dieckmann AK, Oswald M, Eils R, Kupiec M, Luke B, Konig R (2016) Mixed Integer Linear Programming based machine learning approach identifies regulators of telomerase in yeast. Nucleic Acids Res 44: e93 Doi 10.1093/nar/gkw111.

Contact

Alexandra Poos

DKFZ & BioQuant Center

Division of Chromatin Networks

Im Neuenheimer Feld 267-BQ24

69120 Heidelberg

Germany


BioQuant room 641

Tel.: +49-6221-54-51377

Fax: +49 6221 54 51487


e-mail: a.poos (at) dkfz.de
to top of page